Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MG-S-2525
- Development stage
- Phase 1
- Lead developer
- Metagone Biotech
- Modality
- Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Fragment-Derived Small Molecules → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
MG-S-2525 is an oral, small molecule kinase inhibitor developed by Metagone Biotech for the treatment of respiratory diseases, particularly idiopathic pulmonary fibrosis (IPF) and bronchiectasis. It acts as a selective inhibitor of mitogen-activated protein kinase 19 (MAP3K19), a protein highly expressed in lung tissue and implicated in fibrotic and inflammatory processes. Preclinical studies demonstrated that MG-S-2525 effectively reduces fibrosis and inflammation in animal models, outperforming existing therapies such as pirfenidone. The drug has received Orphan Drug Designation from the US FDA for IPF and has completed Phase I clinical trials showing high safety at doses up to 800 mg. As of early 2024, it is in Phase II development for both IPF and bronchiectasis[2][3][8].
- Other names
- 5-(3,5-Dimethyl-4-hydroxybenzylamino)-3-(4-morpholin-4-yl-phenylamino)-1H-pyrazole-4-carboxylic acid amide
Beyond the preview
Go deeper on MG-S-2525.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MG-S-2525.